{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:59Z","timestamp":1761513179274,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jfo.2012.06.007","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T14:01:11Z","timestamp":1345816871000},"page":"695-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Complications infectieuses li\u00e9es au traitement par anti-TNF\u03b1\u00a0: \u00e0 propos de deux cas de leishmaniose"],"prefix":"10.1016","volume":"35","author":[{"given":"E.","family":"Bousquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Villain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Konate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2012.06.007_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2012.06.007_bib0010","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumor necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2012.06.007_bib0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2012.06.007_bib0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2\u00a0to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2012.06.007_bib0025","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2012.06.007_bib0030","first-page":"1787","article-title":"TNF alpha and TNF alpha receptor 1\u00a0in the retina of normal and glaucomatous eyes","volume":"42","author":"Tezel","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2012.06.007_bib0035","first-page":"3873","article-title":"Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin induced uveitis in the rat","volume":"35","author":"De Vos","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2012.06.007_bib0040","first-page":"2462","article-title":"Quantitative assessment of the integrity of the blood-retinal barrier in mice","volume":"43","author":"Derevjanik","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2012.06.007_bib0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfo.2012.06.007_bib0050","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2012.06.007_bib0055","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2012.06.007_bib0060","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in management of Behcet's disease - review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jfo.2012.06.007_bib0175","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Khan","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2012.06.007_bib0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease","volume":"26","author":"Abu El Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2012.06.007_bib0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","article-title":"Behcet's disease: ocular effects and treatment","volume":"27","author":"Deuter","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2012.06.007_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation","volume":"43","author":"Baughman","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jfo.2012.06.007_bib0085","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2012.06.007_bib0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","article-title":"Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation","volume":"27","author":"Theodossiadis","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2012.06.007_bib0095","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2012.06.007_bib0100","first-page":"13","article-title":"Clinical pharmacokinetics of tumor necrosis factor antagonists","volume":"74","author":"Nestorov","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jfo.2012.06.007_bib0105","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"Esser","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfo.2012.06.007_bib0110","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","article-title":"Infliximab-induced lupus in Crohn's disease: a case report","volume":"35","author":"Sarzi-Puttini","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jfo.2012.06.007_bib0115","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2012.06.007_bib0120","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2012.06.007_bib0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2012.06.007_bib0130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.jfo.2012.06.007_bib0135","first-page":"1019","article-title":"Leishmaniasis: update","volume":"29","author":"Dedet","year":"2000","journal-title":"Presse Med"},{"key":"10.1016\/j.jfo.2012.06.007_bib0140","first-page":"255","article-title":"Insect vectors of leishmania: distribution, physiology and their control","volume":"45","author":"Sharma","year":"2008","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.jfo.2012.06.007_bib0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3201\/eid1407.071589","article-title":"Spread of vector-borne diseases and neglect of leishmaniasis, Europe","volume":"14","author":"Dujardin","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jfo.2012.06.007_bib0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.10.2.298","article-title":"Leishmania and human immunodeficiency virus coinfection: the first 10years","volume":"10","author":"Alvar","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jfo.2012.06.007_bib0155","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.micinf.2005.06.002","article-title":"Visceral leishmaniasis in organ transplant recipients: 11\u00a0new cases and review of the literature","volume":"7","author":"Basset","year":"2005","journal-title":"Microb Infect"},{"key":"10.1016\/j.jfo.2012.06.007_bib0160","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.153.2.768","article-title":"Role and effect of TNF alpha in experimental visceral leishmaniasis","volume":"153","author":"Tumang","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.jfo.2012.06.007_bib0165","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3201\/eid1506.090101","article-title":"Leishmaniasis, autoimmune rheumatic disease and anti-tumor necrosis factor therapy, Europe","volume":"15","author":"Xynos","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jfo.2012.06.007_bib0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/jop.2009.0035","article-title":"Ocular safety of infliximab in rabbit and cell culture models","volume":"26","author":"Giansanti","year":"2010","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121200215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155121200215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:02:51Z","timestamp":1759258971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018155121200215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S018155121200215X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2012.06.007","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications infectieuses li\u00e9es au traitement par anti-TNF\u03b1\u00a0: \u00e0 propos de deux cas de leishmaniose","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2012.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}